[Basic study on the chemosensitivity test by miniaturized improved nucleic acid precursor incorporation assay (MINI assay)].
Miniaturized improved nucleic acid precursor incorporation assay (MINI assay) has been developed by Kern D. H. and Tanigawa N. et al since 1985. We investigated in vitro effects of mitomycin C (MMC), cisplatin (CDDP) and bleomycin (BLM) against A 549 lung cancer cells and HeLa cells by MINI assay.


RESULTS
3H-thymidine (3H-TdR) uptake in the positive control was 734.2 cpm +/- 10 cpm. The cut-off level for in vitro sensitivity was defined as more than 80% inhibition of 3H-TdR uptake in the drug treated cells compared to the positive controls. A 549 cells were sensitive to MMC (81.6%), CDDP (78.6%), but not to BLM (-57%). HeLa cells were sensitive to MMC (91%), CDDP (79.4%), but not to BLM (43%). MINI assay could be done with fewer cells than other methods and the results were obtained within 5 days. This method was considered to be useful for the chemosensitivity test with human tumors.
First Dept. of Internal Medicine, Nihon University School of Medicine.
M
M
Mogi
M
M
Motohashi
T
T
Hirota
K
K
Ohshima
N
N
Takahashi
Y
Y
Kinoshita
M
M
Tanigawa
T
T
Yoshinobu
Y
Y
Koya
M
M
Masutani
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000378:metabolism*; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D005069:Evaluation Studies as Topic; D006801:Humans; D066298:In Vitro Techniques; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use; D013936:Thymidine / Q000493:pharmacokinetics; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D008937:Mitomycins; D001761:Bleomycin; D016685:Mitomycin; D002945:Cisplatin; D013936:Thymidine